BUZZ-Aptose Biosciences rises on safety results from early-stage cancer therapy trial

U.S.-listed shares of drug developer Aptose Biosciences APTO.O APS.TO rise 21.57% to 31 cents

Co says its first line combination treatment is safe and tolerable in patients with a type of blood cancer in an early-stage trial

Co is testing its experimental drug tuspetinib in combination with two other standard of care therapies

To date, four patients have received lowest dose (40 mg) of the combination treatment

The once daily therapy is being developed to treat newly diagnosed patients with a type of blood cancer who are ineligible to receive induction chemotherapy

Expects enrollment of 18-24 patients by mid-late 2025

In the last 12 months, the stock down 87.5%